StockData
Adagene Inc. logo

Adagene Inc. (ADAG) company profile

ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 5/30
$1.48−0.12 (-7.50%)

Close on Nov 17, 2026Market cap $87.66MP/E –Yield –

About Adagene

Pharmaceutical Preparations, SIC 2834

Adagene Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based cancer immunotherapies using computational biology. The company utilizes proprietary antibody platforms, including its Dynamic Precision Library, to engineer masked and empowered antibodies such as NEObodies, SAFEbodies, and POWERbodies. Its product pipeline includes clinical candidates like ADG126, an anti-CTLA-4 therapy undergoing clinical trials for solid tumors such as colorectal cancer, alongside earlier-stage candidates including ADG206, ADG138, and ADG116. Adagene collaborates with and out-licenses technologies to global pharmaceutical and biotechnology partners, academic institutions, and healthcare organizations.

The company maintains an international footprint with research, development, and subsidiary entities across China, the United States, Australia, Singapore, and Switzerland. Adagene conducts research and operations through facilities in San Diego, California, and Suzhou, China, with a registered office in the Cayman Islands. Its corporate headquarters is located in Suzhou, China.

Summary of the business section of Adagene's latest annual report, written by StockData.

Company profile

Company

Legal name
Adagene Inc.
Founded
2011
Headquarters
Jiangsu, F4
Address
4f, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park 00000
Phone
86-512-87773632
Employees
128, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers Zhong TianLLP, Shanghai, the Peoples Republic of China

Stock & identifiers

Ticker
ADAG
Exchange
Nasdaq
IPO date
Feb 10, 2021
Shares outstanding
59M, Dec 31, 2025
Filer category
Accelerated filer<br>Emerging growth company
SEC CIK
1818838
CUSIP
005329107
ISIN
US0053291078
FIGI
BBG00YZ6BYJ6
Share class FIGI
BBG00YZ6BZC0
LEI
875500IY38EWGFPSEV72
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Man Kin TamChief Financial Officer, Director12,000
Peter LuoChief Executive Officer, Director194,556
Chunfang GuExecutive Director of Finance15,625
Mickael Yannick Chane-DuChief Strategy Officer467,525
Qinghai ZhaoChief Manufacturing Officer37,500
Ling ZhouED of Human Resources2,969
Cuong V. DoDirector2,000
Andy Yiu Leung CheungDirector–
Li ZhuDirector–
Ulf GrawunderDirector25,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 10, 2021
Securities offered
7,354,000
Exchange
Nasdaq
First trading day
Feb 9, 2021
First-day close
$29.99
Lock-up ends (est.)
Aug 8, 2021

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 128 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?